128 related articles for article (PubMed ID: 9583851)
1. Intravenous lipid dose and incidence of bacteremia and fungemia in patients undergoing bone marrow transplantation.
Lenssen P; Bruemmer BA; Bowden RA; Gooley T; Aker SN; Mattson D
Am J Clin Nutr; 1998 May; 67(5):927-33. PubMed ID: 9583851
[TBL] [Abstract][Full Text] [Related]
2. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome.
Safdar A; van Rhee F; Henslee-Downey JP; Singhal S; Mehta J
Bone Marrow Transplant; 2001 Nov; 28(9):873-8. PubMed ID: 11781648
[TBL] [Abstract][Full Text] [Related]
3. High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy. A study of the American Bone Marrow Transplant Group.
Wolff SN; Fay JW; Herzig RH; Greer JP; Dummer S; Brown RA; Collins RH; Stevens DA; Herzig GP
Ann Intern Med; 1993 Jun; 118(12):937-42. PubMed ID: 8489107
[TBL] [Abstract][Full Text] [Related]
4. A randomized placebo-controlled trial of lisofylline in HLA-identical, sibling-donor, allogeneic bone marrow transplant recipients. The Lisofylline Marrow Transplant Study Group.
List AF; Maziarz R; Stiff P; Jansen J; Liesveld J; Andrews F; Schuster M; Wolff S; Litzow M; Karanes C; Dahlberg S; Kirkhart B; Bianco JA; Singer JW
Bone Marrow Transplant; 2000 Feb; 25(3):283-91. PubMed ID: 10673700
[TBL] [Abstract][Full Text] [Related]
5. Nosocomial colonization, septicemia, and Hickman/Broviac catheter-related infections in bone marrow transplant recipients. A 5-year prospective study.
Elishoov H; Or R; Strauss N; Engelhard D
Medicine (Baltimore); 1998 Mar; 77(2):83-101. PubMed ID: 9556701
[TBL] [Abstract][Full Text] [Related]
6. Analysis of early infectious complications in pediatric patients undergoing bone marrow transplantation.
Busca A; Saroglia EM; Giacchino M; Vai S; Vassallo E; Fagioli F; Linari A; Dotti G; Miniero R; Madon E
Support Care Cancer; 1999 Jul; 7(4):253-9. PubMed ID: 10423051
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation.
Koh LP; Kurup A; Goh YT; Fook-Chong SM; Tan PH
Am J Hematol; 2002 Dec; 71(4):260-7. PubMed ID: 12447954
[TBL] [Abstract][Full Text] [Related]
8. Clinical and metabolic effects of different parenteral nutrition regimens in patients undergoing allogeneic bone marrow transplantation.
Muscaritoli M; Conversano L; Torelli GF; Arcese W; Capria S; Cangiano C; Falcone C; Rossi Fanelli F
Transplantation; 1998 Sep; 66(5):610-6. PubMed ID: 9753341
[TBL] [Abstract][Full Text] [Related]
9. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation.
Winston DJ; Antin JH; Wolff SN; Bierer BE; Small T; Miller KB; Linker C; Kaizer H; Lazarus HM; Petersen FB; Cowan MJ; Ho WG; Wingard JR; Schiller GJ; Territo MC; Jiao J; Petrarca MA; Tonetta SA
Bone Marrow Transplant; 2001 Jul; 28(2):187-96. PubMed ID: 11509937
[TBL] [Abstract][Full Text] [Related]
10. Effect of mixed chimerism on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia.
Huss R; Deeg HJ; Gooley T; Bryant E; Leisenring W; Clift R; Buckner CD; Martin P; Storb R; Appelbaum FR
Bone Marrow Transplant; 1996 Oct; 18(4):767-76. PubMed ID: 8899193
[TBL] [Abstract][Full Text] [Related]
11. Incidence, risk factors, and outcome of bloodstream infections during the pre-engraftment phase in 521 allogeneic hematopoietic stem cell transplantations.
Blennow O; Ljungman P; Sparrelid E; Mattsson J; Remberger M
Transpl Infect Dis; 2014 Feb; 16(1):106-14. PubMed ID: 24372809
[TBL] [Abstract][Full Text] [Related]
12. Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group.
Wolff SN; Fay J; Stevens D; Herzig RH; Pohlman B; Bolwell B; Lynch J; Ericson S; Freytes CO; LeMaistre F; Collins R; Pineiro L; Greer J; Stein R; Goodman SA; Dummer S
Bone Marrow Transplant; 2000 Apr; 25(8):853-9. PubMed ID: 10808206
[TBL] [Abstract][Full Text] [Related]
13. Bloodstream and central line isolates from hematopoietic stem cell transplant recipients: data from a developing country.
Ali N; Adil SN; Shaikh MU
Transpl Infect Dis; 2014 Feb; 16(1):98-105. PubMed ID: 24383473
[TBL] [Abstract][Full Text] [Related]
14. A comparison of related donor peripheral blood and bone marrow transplants: importance of late-onset chronic graft-versus-host disease and infections.
Anderson D; DeFor T; Burns L; McGlave P; Miller J; Wagner J; Weisdorf D
Biol Blood Marrow Transplant; 2003 Jan; 9(1):52-9. PubMed ID: 12533742
[TBL] [Abstract][Full Text] [Related]
15. A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery.
Sullivan KM; Storek J; Kopecky KJ; Jocom J; Longton G; Flowers M; Siadak M; Nims J; Witherspoon RP; Anasetti C; Appelbaum FR; Bowden RA; Buckner CD; Crawford SW; Deeg HJ; Hansen JA; McDonald GB; Sanders JE; Storb R
Biol Blood Marrow Transplant; 1996 Feb; 2(1):44-53. PubMed ID: 9078354
[TBL] [Abstract][Full Text] [Related]
16. Improved graft-versus-host disease-free, relapse-free survival associated with bone marrow as the stem cell source in adults.
Mehta RS; Peffault de Latour R; DeFor TE; Robin M; Lazaryan A; Xhaard A; Bejanyan N; de Fontbrune FS; Arora M; Brunstein CG; Blazar BR; Weisdorf DJ; MacMillan ML; Socie G; Holtan SG
Haematologica; 2016 Jun; 101(6):764-72. PubMed ID: 27036159
[TBL] [Abstract][Full Text] [Related]
17. Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups.
Inamoto Y; Kimura F; Kanda J; Sugita J; Ikegame K; Nakasone H; Nannya Y; Uchida N; Fukuda T; Yoshioka K; Ozawa Y; Kawano I; Atsuta Y; Kato K; Ichinohe T; Inoue M; Teshima T;
Haematologica; 2016 Dec; 101(12):1592-1602. PubMed ID: 27662017
[TBL] [Abstract][Full Text] [Related]
18. Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors.
Young JH; Logan BR; Wu J; Wingard JR; Weisdorf DJ; Mudrick C; Knust K; Horowitz MM; Confer DL; Dubberke ER; Pergam SA; Marty FM; Strasfeld LM; Brown JWM; Langston AA; Schuster MG; Kaul DR; Martin SI; Anasetti C;
Biol Blood Marrow Transplant; 2016 Feb; 22(2):359-370. PubMed ID: 26409243
[TBL] [Abstract][Full Text] [Related]
19. Bloodstream infections can develop late (after day 100) and/or in the absence of neutropenia in children receiving allogeneic bone marrow transplantation.
Romano V; Castagnola E; Dallorso S; Lanino E; Calvi A; Silvestro S; Morreale G; Giacchino R; Dini G
Bone Marrow Transplant; 1999 Feb; 23(3):271-5. PubMed ID: 10084259
[TBL] [Abstract][Full Text] [Related]
20. Early vancomycin-resistant enterococcus (VRE) bacteremia after allogeneic bone marrow transplantation is associated with a rapidly deteriorating clinical course.
Avery R; Kalaycio M; Pohlman B; Sobecks R; Kuczkowski E; Andresen S; Mossad S; Shamp J; Curtis J; Kosar J; Sands K; Serafin M; Bolwell B
Bone Marrow Transplant; 2005 Mar; 35(5):497-9. PubMed ID: 15640812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
